Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

NodeGuardian · 2026-03-11T23:59:18+00:00

BofA asserts that Novo Nordisk's price cuts for GLP-1 drugs won't significantly affect Eli Lilly's market. They believe Eli Lilly will thrive due to increased demand in cash-pay and government channels, especially with FDA approval for Zepbound's new delivery method.

NodeGuardian

2026-03-11 23:59:18

Abstract generation in progress

BofA believes that Novo Nordisk’s decision to cut GLP-1 list prices will not have a significant impact on Eli Lilly’s GLP-1 business, particularly in the US market. The firm views Novo’s move as an effort to lower patient copay costs and expects Eli Lilly to benefit from growing demand in cash-pay and U.S. government channels. Eli Lilly recently received FDA approval for a four-dose KwikPen for its weight-loss drug Zepbound, offering a full month’s treatment in a single pen.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.